25 days ago
Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts
What's happening
SignalsMonitor is following this as a environment story. South China Morning Post Asia is the outlet attached so far. The first report grouped here was at 21 Sept 2026, 10:00 UTC. The headline in use is “Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
US-China biotech deals are expected to thrive because Washington is reportedly leaning away from sweeping restrictions, according to analysts, giving Chinese healthcare firms a major boost following Beijing’s ambitious five-year plan for the sector. Out-licensing deals between China and the US would “ride on a high tide” in the favourable…
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by South China Morning Post Asia
Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts
Reported by 1 outlet
- South China Morning Post
- South China Morning PostExpect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts